Clinical Trial News and Research

RSS

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Cinterion Wireless Modules, the global leader in cellular machine-to-machine (M2M) communication modules, and Diabetech, the leader in patient-centric health care programs, today announced their collaboration on the fourth generation GlucoMON® platform, the world’s easiest-to-use wireless diabetes management system designed to help the over 220 million people worldwide struggling to manage the global diabetes and pre-diabetes pandemic.

7 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.

From Baxter International Inc. 7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

7 Oct 2009

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).

7 Oct 2009

CE Mark approval for AtriClip System

AtriCure, Inc. a medical device company and a leader in cardiac surgical ablation systems, today announced CE Mark approval for its AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion System.

7 Oct 2009

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced positive top-line clinical results for its lead pain drug Ketotransdel®( )in a Phase 3 trial which evaluated the efficacy and safety of the drug in acute soft tissue injuries of the upper and lower extremities.

6 Oct 2009

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.

6 Oct 2009

Direct Flow Medical releases clinical results of its new Percutaneous Aortic Valve System

Direct Flow Medical, Inc., www.directflowmedical.com, released its 12 month data from the initial clinical trial for a new device to treat valve disease without invasive thoracic surgery. Direct Flow Medical is a privately held, emerging medical device company developing a next-generation, catheter based, percutaneous delivered prosthetic aortic valve.

6 Oct 2009

Boston Scientific begins patient enrollments for MADIT-RIT clinical trial

Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.

6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

Two-thirds of tonsil tumour samples show evidence of HPV-16 gene: Study

It is estimated that more than 7,000 people are diagnosed with head and neck cancer each year in the UK and approximately 3,500 cases result in death. These cancers include tumours of the mouth, lips, throat and voice-box, and some have been linked to the sexually transmitted infection, HPV-16. Scientists at Liverpool analysed the DNA of more than 90 cancerous tissue samples to look for genes that indicated infection.

6 Oct 2009

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Pico-Tesla commences Phase III clinical trial its Resonator system for treating Parkinson’s disease

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a Phase III clinical trial of its patented Resonator™ system that facilitates the Company’s proprietary magnetic (Magneceutical™) therapy for treating Parkinson’s disease patients.

6 Oct 2009

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk.

6 Oct 2009

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.

6 Oct 2009

Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

Cumberland Pharmaceuticals Inc. announced today that data from two key clinical trials for Caldolor®, an intravenous formulation of ibuprofen approved for treatment of pain and fever in adults, will be presented at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting to be held in Phoenix, Ariz., on October 8-11, 2009.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

Today, at the American Academy of Otolaryngology-Head and Neck Surgery annual meeting, ImThera Medical, Inc. unveiled its new product, the aura6000™ neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA).

5 Oct 2009

Clinical Trial News and Research

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

CE Mark approval for AtriClip System

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

Direct Flow Medical releases clinical results of its new Percutaneous Aortic Valve System

Boston Scientific begins patient enrollments for MADIT-RIT clinical trial

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

Two-thirds of tonsil tumour samples show evidence of HPV-16 gene: Study

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

Pico-Tesla commences Phase III clinical trial its Resonator system for treating Parkinson’s disease

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery